Nebacumab Biosimilar – Anti-Endotoxin mAb – Research Grade from ProteoGenix; catalogue PX-TA1145; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Nebacumab Biosimilar – Anti-Endotoxin mAb – Research Grade is a monoclonal antibody (mAb) that has been developed as a biosimilar to the original drug Nebacumab. This biosimilar is designed to target endotoxins, which are toxic substances produced by certain bacteria and can cause severe inflammatory reactions in the body. In this article, we will explore the structure, activity, and potential applications of Nebacumab Biosimilar.
Nebacumab Biosimilar is a recombinant humanized IgG1 monoclonal antibody with a molecular weight of approximately 150 kDa. It is composed of two heavy chains and two light chains, each containing a variable and a constant region. The variable region is responsible for binding to the target endotoxins, while the constant region determines the antibody’s effector functions.
The structure of Nebacumab Biosimilar is highly similar to the original drug Nebacumab, with minor differences in the amino acid sequence. This is important in ensuring the biosimilar’s similarity to the original drug and its ability to target endotoxins effectively.
Nebacumab Biosimilar works by binding to endotoxins and neutralizing their toxic effects. Endotoxins are molecules found on the outer membrane of certain bacteria and can trigger a strong immune response in the body. This response can lead to severe inflammation, tissue damage, and even septic shock.
By binding to endotoxins, Nebacumab Biosimilar prevents them from interacting with immune cells and triggering an inflammatory response. This can help reduce the severity of symptoms and improve patient outcomes in conditions caused by endotoxins, such as sepsis.
Title: Applications of Nebacumab Biosimilar – Anti-Endotoxin mAb – Research Grade Nebacumab Biosimilar has potential applications in the treatment of various conditions caused by endotoxins, including sepsis, septic shock, and other inflammatory disorders. It can also be used in conjunction with antibiotics to enhance their effectiveness in treating bacterial infections.
In addition, Nebacumab Biosimilar can be used in research settings to study the role of endotoxins in various diseases and to develop new therapeutic strategies targeting endotoxins.
One of the main advantages of Nebacumab Biosimilar is its cost-effectiveness compared to the original drug. Biosimilars are typically more affordable than their reference products, making them more accessible to patients and healthcare systems.
Moreover, Nebacumab Biosimilar has been extensively studied and shown to have similar safety and efficacy profiles as the original drug. This provides reassurance to healthcare providers and patients regarding its effectiveness in treating endotoxin-related conditions.
In conclusion, Nebacumab Biosimilar – Anti-Endotoxin mAb – Research Grade is a promising biosimilar that has the potential to improve patient outcomes in conditions caused by endotoxins. Its similar structure and activity to the original drug, along with its cost-effectiveness, make it a valuable addition to the treatment options for endotoxin-related diseases. Further research and clinical trials are needed to fully explore the potential of this biosimilar in treating various inflammatory disorders.
ProteoGenix catalogue number PX-TA1145. For research use only.
Target: Nebacumab Biosimilar – Anti-Endotoxin mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: Mammalian cells; Purity: >85%; Buffer: PBS buffer PH7.5; Applications: ELISA, WB.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Nebacumab Biosimilar – Anti-Endotoxin mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
